Holen Sie sich die Stockscreener-App
8.62
4.74%
0.39
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
Regenxbio (RGNX) Maintains Strong Outlook Amid Competitor Safety Concerns | RGNX Stock News - GuruFocus
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO (RGNX) Prepares for Potential $4M Warrant Cash Influx - GuruFocus
Regenxbio (RGNX) Proposes Sale of Over 268,000 Shares | RGNX Stock News - GuruFocus
Regenxbio (RGNX) Maintains Buy Rating with $52 Price Target | RGNX Stock News - GuruFocus
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts - Benzinga
Promising RGX-202 Trial Results Justify Buy Rating for RegenXBio Amid Market Skepticism - TipRanks
REGENXBIO updates Phase 1/2 data for Duchenne candidate - MSN
Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha
H.C. WAINWRIGHT MAINTAINS BUY RATING ON REGENXBIO STOCK AFTER POSITIVE TRIAL DATA - Investing.com Nigeria
Duchenne gene therapy interim trial outcomes "striking" - MarketScreener
Otsuka tops Vera with kidney drug data; Regenxbio sinks on Duchenne update - BioPharma Dive
RegeNXBio shares fall, despite positive new data on RGX-202 - The Pharma Letter
REGENXBIO reports progress in Duchenne treatment trial By Investing.com - Investing.com South Africa
Regenxbio’s Duchenne gene therapy data positive as shares falter - BioWorld MedTech
New Regenxbio DMD Data Support Gene Therapy Accelerated Approval - insights.citeline.com
Stifel reiterates Buy rating on Regenxbio stock after trial data By Investing.com - Investing.com Nigeria
Stifel reiterates Buy rating on Regenxbio stock after trial data - Investing.com Australia
REGENXBIO reports new positive functional data from phase I/II AFFINITY Duchenne® trial of RGX-202 - Pipelinereview
Regenxbio’s Gene Therapy Helps Kids with Deadly Muscle Disease - Bloomberg
Transcript : REGENXBIO Inc.Special Call - MarketScreener
Regenxbio (RGNX) Reports Positive Data for RGX-202 Gene Therapy Trial - GuruFocus
Regenxbio (RGNX) Reports Promising Interim Results for Duchenne Therapy | RGNX Stock News - GuruFocus
REGENXBIO reports progress in Duchenne treatment trial - Investing.com Australia
REGENXBIO stock in focus after data for Duchenne drug (RGNX) - Seeking Alpha
Regenxbio Reports New Positive Functional Data From Phase I/Ii Affinity Duchenne® Trial Of Rgx-202 - MarketScreener
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II A - GuruFocus
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 | RGNX Stock News - GuruFocus
REGENXBIO REPORTS NEW POSITIVE FUNCTIONAL DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 - PR Newswire
RegenXBio Holds 2025 Annual Stockholders Meeting - TipRanks
ProShare Advisors LLC Boosts Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
Bank of America Corp DE Reduces Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 - Eagle-Tribune
REGENXBIO to Host Webcast Discussing Interim Functional Data fro - GuruFocus
REGENXBIO to Host Webcast Discussing Interim Functional Data from the Phase I/II AFFINITY DUCHENNE® Trial of RGX-202 | RGNX Stock News - GuruFocus
Leerink Partnrs Weighs in on REGENXBIO FY2026 Earnings - Defense World
Ameriprise Financial Inc. Has $2.20 Million Stake in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $775,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX) - Defense World
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com UK
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO Inc. (NASDAQ:RGNX) Shares Bought by Deutsche Bank AG - Defense World
Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
1.45%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):